Loading clinical trials...
Loading clinical trials...
Perioperative Immunoagent (Tislelizumab) Plus Chemotherapy for Locally Advanced Resectable Thoracic Oesophageal Squamous Cell Carcinoma Trail:A Prospective Single-arm,Phase II Study (PILOT Trail)
Conditions
Interventions
Tislelizumab
Locations
1
China
Shanghai chest hospital
Shanghai, Shanghai Municipality, China
Start Date
September 7, 2023
Primary Completion Date
September 30, 2024
Completion Date
December 31, 2026
Last Updated
September 28, 2023
NCT07463573
NCT07528066
NCT07388771
NCT06747585
NCT04511039
NCT07437898
Lead Sponsor
Guo Xufeng
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions